“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

Global Nanotechnology Drug Delivery Market is valued at USD 85.5 Billion in 2022. Global Nanotechnology Drug Delivery Market ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

Kenox and Lactiga US have announced a strategic partnership for progressing new mucosal-targeted sIgA therapies development.

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

"Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug ...